SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Cequent Pharmaceuticals, Inc. Files its First IND with FDA: CEQ508, a tkRNAi Drug Candidate in Oncology First Orally Delivered RNAi Investigational Drug to be Tested in Humans